DMAA (Drugs Made In America Acquisition) Accounts Receivable: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAA Drugs Made In America Acquisition Corp DMAA
14 GF Score
Price $10.71
! 1 Warning Sign
View Full Analysis

What is Drugs Made In America Acquisition Accounts Receivable?

Drugs Made In America Acquisition DMAA 14 Accounts Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates DMAA with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Drugs Made In America Acquisition's accounts receivables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Drugs Made In America Acquisition's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $-0.22.


Drugs Made In America Acquisition Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Drugs Made In America Acquisition's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Drugs Made In America Acquisition's accounts receivable are only considered to be worth 75% of book value:

Drugs Made In America Acquisition's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.015+0.75 * 0+0.5 * 0-7.392
-0-0)/33.717
=-0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Drugs Made In America Acquisition Accounts Receivable Related Terms


Drugs Made In America Acquisition Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Drugs Made In America Acquisition's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drugs Made In America Acquisition Accounts Receivable Chart

Drugs Made In America Acquisition Annual Data
Trend Dec24 Dec25
Accounts Receivable
0.00 0.00

Drugs Made In America Acquisition Quarterly Data
Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
DMAA
14GF Score
Drugs Made In America Acquisition Corp DMAA
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Drugs Made In America Acquisition Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of $0.00 Mil mean?
Drugs Made In America Acquisition (DMAA) has a Accounts Receivable of $0.00 Mil as of Mar. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Drugs Made In America Acquisition and its competitors.
Is Drugs Made In America Acquisition's Accounts Receivable too high?
Drugs Made In America Acquisition's current Accounts Receivable is $0.00 Mil. Overall, Drugs Made In America Acquisition has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition's Accounts Receivable compare to FACT and NTWO?
Drugs Made In America Acquisition's Accounts Receivable of $0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Diversified Financial Services company?
A good Accounts Receivable depends on the Diversified Financial Services industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Drugs Made In America Acquisition and its competitors. Drugs Made In America Acquisition's current Accounts Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition stock overvalued right now?
Drugs Made In America Acquisition (DMAA) has a current Accounts Receivable of $0.00 Mil. The current Accounts Receivable is $0.00 Mil. Drugs Made In America Acquisition's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Drugs Made In America Acquisition (DMAA), the current Accounts Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition Corp is a blank check company.
14GF Score

Get the complete analysis for DMAA

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.71
Price